Preventing muscle and bone loss in peri-menopausal and early post-menopausal females with heavy strength and impact training: Results from the STOP-EM randomised waitlisted controlled feasibility trial Authors: Patrick W Whitman, Christina J Alexander, Leah Kaluta, Meghan H McDonough, Matthew J Jordan, Emma O Billington, Lauren A Burt, Leigh Gabel Published: 2026 ABSTRACT AbstractPurposeDuring the menopausal transition, female individuals experience declines in bone health. Menopausal female individuals also lose lean mass due to aging; however, few exercise trials have included peri- and early post-menopausal participants. The main objective of this study was to explore changes in prespecified secondary muscle and bone outcomes of the Strength Training for Osteoporosis Prevention during Early Menopause (STOP-EM) feasibility trial.MethodsSTOP-EM was a randomised waitlisted controlled feasibility trial completed in Calgary, Canada. Participants were randomised to either a 9-month, twice-weekly, supervised progressive heavy strength (80–85% one-repetition maximum (1RM)) and impact (drop landings) training program (n = 20) or the waitlisted controlled group (n = 20). Inclusion criteria included being between 45 and 60 years old and peri- or early post-menopausal. Outcome assessors were blinded to group allocation, while participants were not blinded. Outcomes included lean mass, muscle strength, leg power output, and areal bone mineral density (aBMD).ResultsAt baseline, mean age was 52.9 (SD: 4.1), 47.5% were peri-menopausal, and 7.5% were on menopausal hormone therapy. All 20 intervention participants and 18 waitlisted controlled participants returned at follow-up. 1RM improved by 12.6% to 30.5% for chest press, shoulder press, deadlift, and back squat lifts. The intervention group experienced increases in total body lean mass (between-group difference for change (95% CI) = 0.90 kg (0.08 to 1.72)), absolute leg power output (97 W (2 to 193)), and lumbar spine aBMD (0.020 g/cm2 (0.001 to 0.034)) compared to the waitlisted controlled group.ConclusionsNine months of heavy strength and impact training increased lean mass, muscle strength, leg power output, and lumbar spine aBMD. These promising results warrant a definitive trial to assess the program's efficacy.Keywords: Bone mineral density, Lean mass, Menopause, Strength training, Menopausal symptoms, Randomised controlled trial Introduction Prior to menopause, female individuals1 can experience several years of irregular menstrual cycles and hormonal fluctuations (Harlow et al., 2012). This stage is called peri-menopause, and lasts until 12 consecutive months without menses (menopause), after which the individual is considered post-menopausal (Harlow et al., 2012). The first five years following menopause is known as early post-menopause, while the remainder of one's life is considered late post-menopause (Harlow et al., 2012). Menopause signifies the cessation of ovulation and, consequently, is accompanied by significant decreases in gonadal estrogen levels (Baber et al., 2016). Declines in estrogen lead to decreases in bone mineral density (BMD) throughout the menopause transition (Messier et al., 2011; Juppi et al., 2020), an increased risk and prevalence of osteoporosis in female individuals compared to male individuals (Hernlund et al., 2013), and an increased prevalence in post-menopausal versus pre-menopausal individuals (Fan et al., 2024). Simultaneously, female individuals experience declines in lean mass due to aging and have a greater prevalence of sarcopenia, the loss of lean mass and muscle strength due to aging compared to male individuals (Janssen et al., 2002). While much research has investigated the effects of exercise on bone health in late post-menopausal females (Kistler-Fischbacher et al., 2021), few exercise trials have focused on the early stages of menopause (Whitman et al., 2025). Therefore, the effectiveness of exercise as a preventative measure against lean mass and bone loss experienced during the menopause transition remains poorly understood. A recommended approach to combat the loss of lean and bone mass is to perform exercise, specifically strength training. Progressive strength training for at least 10–12 weeks is an effective method for building lean mass and strength in early and late post-menopausal females (Khalafi et al., 2023; Stark et al., 2012), whether performed with light- or heavy loads (Bemben et al., 2000). High-intensity resistance and impact training (HiRIT) was effective for increasing areal BMD (aBMD) at the lumbar spine and femoral neck in late post-menopausal female participants (Watson et al., 2018). Additionally, hypertrophy-based strength training using three sets of 8–12 repetitions increased aBMD at the lumbar spine, total hip, femoral neck, and greater trochanter in early post-menopausal females (Maddalozzo et al., 2007). A recent systematic review found that no studies examined heavy strength training or impact training in peri- or early post-menopausal female participants (Whitman et al., 2025). Therefore, using an intervention similar to the HIRIT intervention in the Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation (LIFTMOR) study (Watson et al., 2018), we conducted a randomised waitlisted controlled feasibility trial of a 9-month heavy strength and impact training intervention in peri- and early post-menopausal female participants (Alexander et al., 2025). Here, we report changes in lean mass, muscle strength, leg power output, and aBMD after nine months of heavy strength and impact training. We hypothesized heavy strength and impact training would prevent the loss of lean mass, muscle strength, leg power output, and aBMD, while the waitlisted controlled group maintaining their usual physical activity would experience declines in lean mass, muscle strength, leg power output, and aBMD. We also report changes in balance, cardiorespiratory fitness, menopausal symptoms, and quality of life (QoL). We hypothesized heavy strength and impact training would improve balance, menopausal symptoms, and QoL, but not cardiorespiratory fitness. These results will inform the design of a future definitive trial by identifying trends and refining outcome measures. Methods Study design This study explored prespecified secondary outcomes from a randomised waitlisted controlled feasibility trial (Strength Training for Osteoporosis Prevention during Early Menopause (STOP-EM): a pilot study, ClinicalTrials.gov: NCT05961371). The primary outcomes of the overall trial included assessing recruitment rates, attendance, and attrition to inform the design of a larger definitive trial. The protocol, study design, and methods are described in detail elsewhere (Alexander et al., 2025). Although previous work demonstrated the feasibility and efficacy of HiRIT in late post-menopausal females (Watson et al., 2018), our feasibility trial was necessary to understand whether peri- and early post-menopausal females, who may have more constraints on their time (e.g., employment and caregiving) (Kaluta et al., 2025), are interested in and able to attend twice-weekly in-person exercise sessions. The University of Calgary Conjoint Health Research Ethics Board approved the study (REB22-1632), and all participants gave written informed consent. We report findings following the Consolidated Standards of Reporting Trials (CONSORT 2010 statement: extension to randomised pilot and feasibility trials) (Eldridge et al., 2016). After completing baseline measures, a computer algorithm block randomised participants (four participants per block) to the intervention group (INT) or the waitlisted controlled group (WC) in a 1:1 ratio, stratified by menopausal status (peri- or early post-menopausal) and current menopausal hormone therapy (MHT) use (yes or no). All outcome assessors were blinded throughout the study, while intervention trainers were blinded to participant IDs throughout the study, and participants were not blinded. Study data were collected and managed by the unblinded research coordinator using REDCap electronic data capture tools hosted at University of Calgary (Harris et al., 2019; Harris et al., 2009). REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources. Participants Recruitment started September 2023 and ended February 2024. Follow-up assessments ended on January 2025. Participants were primarily recruited via social media or word of mouth and were screened for eligibility prior to invitation for baseline assessments. Inclusion criteria for the study were: 1) between 45 and 60 years old, and 2) either peri- or early post-menopausal according to the stages for reproductive aging 10+ staging system. Peri-menopause was defined as a variable cycle length of ≥7-day difference between consecutive cycles, or if the individual had a menstrual cycle in the last 12 months but not the last 60 days (Harlow et al., 2012). Early post-menopause was defined as the first five years after 12 consecutive months without menses (Harlow et al., 2012). Participants were excluded from the study if they: 1) were pregnant or planning pregnancy within the 9-month intervention timeframe, 2) had orthopaedic conditions that worsened with exercise, 3) experienced low back pain, type 1 diabetes, unmanaged hypertension, lipidaemia or cardiovascular disease, 4) had a history of metabolic bone disease, 5) had sustained a low-trauma fracture within the last five years prior to the start of the study, 6) had previous pharmacotherapy treatment for osteoporosis, 7) were taking glucocorticoids prior to the start of the study, 8) had low serum vitamin D < 30 nmol/L or serum calcium < 2.10 mmol/L, or 9) had recently (within six months prior to the start of the study) participated in progressive strength training. The research coordinator acquired consent prior to data collection at the beginning of each participant's baseline assessment. Intervention group (INT) The INT performed a twice-weekly progressive heavy strength and impact training over nine months. Each session was in-person at the University of Calgary's research exercise centre and supervised by either a Canadian Society for Exercise Physiology (CSEP) clinical exercise physiologist or a certified personal trainer. The program was delivered in five phases: (1) a 1-month foundation phase which consisted of movement patterning and full range of motion training to establish proper exercise technique, (2) a 2-month building phase, where loads were introduced to the previously learned movements in the foundation phase, and (3) three 8-week strength phase cycles where participants performed five sets of five repetitions at 80–85% of their one-repetition maximum (1RM) (Fig. A.1). The 1-h sessions consisted roughly of a 10-min warm-up, 45 min of a combination of four primary lifts, drop landings, and balance and core exercises, and a 5-min cooldown. Drop landings began as calf raises to heel drops during the building phase and progressed to dropping from a 7-in. platform during the first strength phase before increasing platform heights to the participants' comfort level during the second and third strength phases. Resistance bands and foam rollers were used during the warm-up for each session. Exercises performed at each session included a modified barbell deadlift off a platform and back squat to a box, as well as one of either a bench press or shoulder press, and one of either an assisted pull-up or a single arm bent over row (Alexander et al., 2025). Once participants were able to complete five sets of five repetitions at 85% of their 1RM, load progressed by 5%. 1RM testing was completed by the lead trainer and tested at weeks 12, 20, 28, and 36, where participants performed a 1RM for the deadlift, back squat, chest press, and shoulder press (Alexander et al., 2025). Three warm-up sets were completed in the following order: the first set was 10 repetitions at 50% of predicted 1RM and a rating of perceived exertion (RPE) of 5–6; the second set was five repetitions at 65–75% of the participants predicted 1RM and a rating of RPE of 6–7; the third set was two repetitions at the weight participants worked at during week six of the building phase and first, second, and third strength phases. After completing the warm-up sets, participants attempted to complete one repetition with a 2.5–5% increase in weight from the final warm-up set. The weight was increased by 2.5–5% until the participant could not complete the lift with proper form or rated it 9–10 on the RPE scale. The trainer aimed to achieve 1RM in five attempts or less and participants had two minutes of rest between warm-up sets and three minutes of rest between 1RM attempts. 1RM testing was not conducted for single arm bent over rows nor assisted pull-ups. The intensity prescription for these exercises was based on a weight at which participants reported an RPE of 9 to 10 on their last repetition. Waitlisted controlled group (WC) The WC participants were instructed to maintain their current lifestyle. After the 9-month wait, WC participants were offered the exercise program. Outcome measures Data were collected at the McCaig Institute for Bone and Joint Health at the University of Calgary's Foothills Hospital campus. All tests performed have been validated for this demographic (Enright and Sherrill, 1998; Grgic et al., 2020; Peolsson et al., 2001; Rittweger et al., 2004; Valovich-mcLeod et al., 2004; Hilditch et al., 1996; Jenabi et al., 2015) except for the four-square-step test (FSST), which has been validated in older populations for fall risk (Cleary and Skornyakov, 2017). Anthropometrics Height and weight were measured using a stadiometer (SECO model 222, Hamburg, Germany) and a scale (SECA model 860, Hamburg, Germany). Total body bone-free lean mass (including muscle, organs, and water) (kg) was measured with dual X-ray absorptiometry (DXA) (GE Lunar iDXA, GE Healthcare, Chicago, Illinois, USA) scans of the total body. Appendicular lean mass (kg) was calculated using total arm and leg lean mass (kg) and appendicular lean mass index (ALMI) as lean mass per height squared (kg/m2). aBMD (g/cm2) was measured using DXA scans at the lumbar spine (L1-L4), and left femoral neck and total hip. Low bone mass and osteoporosis were defined as T-scores below or equal to −1 and − 2.5, respectively (Kirk et al., 2019). Low bone mass and osteoporosis were determined using the participant's lowest T-score (Raef et al., 2011). Coefficient of variation (CV) for lean mass and fat mass are 0.5% and 0.8%, respectively (Hind et al., 2011), and range from 0.5 to 1.1% for aBMD (Burt et al., 2025). Muscle strength and leg power In addition to 1RM, a maximal voluntary isometric contraction (MVIC) of knee extension was measured in all participants using a Biodex System 4 Pro isometric dynamometer (Biodex Medical Systems, Shirley, New York, USA). Two sets of three repetitions were performed, the first set being a familiarisation set. During the familiarisation set, participants had their non-dominant leg positioned at a 90° angle and extended their leg at 50% of their perceived maximum. During the second set, participants extended their leg to their perceived 100%. Each repetition was five seconds long, with 1-min breaks between each attempt. Participants' maximum attempt during the second set (N•m) was used for analysis (Alexander et al., 2025). CV for isometric knee extensions has previously been reported to be between 4.2 and 5.0% (Zech et al., 2008). Handgrip strength from both hands was measured for all participants using a hydraulic hand dynamometer (JAMAR®, Performance Health, Warrenville, USA). Elbows were flexed at 90° and participants had one practice attempt and two recorded attempts for each hand. Participants squeezed the dynamometer as hard as possible for three seconds with 15-second breaks between each attempt. The maximum attempt was analysed and reported, in kg, for the dominant and non-dominant hand. Sarcopenia was defined as per the European consensus on definition and diagnosis, as ALMI below 5.67 kg/m2 and handgrip strength <20 kg (Cruz-Jentoft et al., 2010). CV for handgrip strength has previously been reported as 4.1% (Sartorio et al., 2025). Leg power output was measured during countermovement jump (CMJ) testing on a Leonardo Mechanograph force plate (Novotec Medical GmbH, Baden-Württemberg, Germany). Participants performed two sets of three attempts, the first was a familiarisation set, and the second the testing set. Participants stood on the force plate, feet hip-width apart, with their hands on their hips. After a 5-s delay, participants initiated their CMJ. The peak external mechanical power (W) was calculated as the product of force and velocity (Rittweger et al., 2004) at a sampling rate of 800 Hz. The highest peak external mechanical power during the second set was used for analysis (Alexander et al., 2025). CV for peak power has previously been reported as <0.5% (Matheson et al., 2013). Functional tests Functional balance was measured with a FSST, where participants' fastest attempt was used for analysis. The FSST is a test of functional balance where participants are asked to step over 1-inch diameter sticks placed on the ground to create four quadrants. To perform the FSST, participants completed the following sequence as fast as possible while avoiding the sticks: from square I, step forward into square II, then sideways into square III, backward into square IV, sideways into square I, then from square I step sideways into square IV, forward into square III, sideways into square II and finally backwards into square I (Alexander et al., 2025). Participants had to ensure both feet were in each square before moving to the next, and could not run, jump or jog when completing the test. Participants had one practice attempt and two recorded attempts, with 15-second breaks between each attempt. V̇O2max (mL/kg/min) was estimated from a 6-minute-walk test (6MWT) that consisted of completing as many laps as possible between two cones set 25 m apart. Mänttäri's equation was used for analysis (Mänttäri et al., 2018): Physical activity (PA) was measured with GT9X accelerometers (ActiGraph, Pensacola, Florida, USA). Participants wore accelerometers on their right hip for seven days. Minimum wear time requirements were set at eight hours per day, for a minimum of three days, including one weekend day. Sixty minutes of consecutive zeros was used to define non-wear time. Epoch length was one second. To include sedentary behaviour, we changed which Freedson cutpoints we used for analysis from what we previously published in the protocol (Alexander et al., 2025). The cutpoint for sedentary time was <100 counts per minute (CPM) and the cutpoint for moderate-to-vigorous PA (MVPA) was >1952 CPM (Freedson et al., 1998). Sedentary time and MVPA time were used for descriptive statistics. Menopausal symptoms and Quality of Life (QoL) Menopausal symptoms were assessed pre- and post- intervention using the Menopause-Specific Quality of Life (MENQoL) questionnaire (Hilditch et al., 1996; Schultz et al., 2024), covering four domains: vasomotor (e.g., night sweats, hot flashes), psychosocial (e.g., life dissatisfaction, anxiety), physical (e.g., muscle and joint pain, sleep issues), and sexual (e.g., changes in sexual desire, vaginal dryness). Scores ranged from 1 to 8 and mean scores were calculated for each domain. If participants reported not experiencing a symptom, “No”, they scored a 1. If they experienced a symptom, “Yes”, they scored a 2 plus an additional rating on how bothersome the symptom was, from “0 - not bothered at all” to “6 - extremely bothered”. Higher scores indicated more severe symptoms. A decrease in score indicates less bothersome symptoms at follow-up. QoL was assessed pre- and post-intervention using the 36-Item Short Form Health Survey (SF-36), which assesses eight domains: physical functioning (impact of health on daily physical activities); role physical (effect of physical health on work and leisure activities); role emotional (impact of emotional health on work and leisure activities); energy and fatigue (levels of vitality and tiredness); mental health (mood, depression, anxiety); social functioning (effect of physical and emotional health interfering with social activities); pain (perceptions of pain intensity and interference with daily activities); general health (perception of overall health); health change (perception of change in health compared to previous year). The questionnaire includes 36 items measured using various Likert and true and false scales, and scores for each domain are calculated followed the scoring key (Brazier et al., 1992; Anon, n.d.). Increases in individual domain QoL scores indicate improved perceived health in that domain at follow-up. Sample size and statistical analysis Sample size calculations were based on feasibility outcomes using a traffic light system with a 1-sided alpha of 5% and power of 80%. Progression criteria included recruitment >50%, retention >85%, and adherence >80%, while stop criteria included recruitment <35%, retention <65%, and adherence <60%. A total of n = 68 screened participants were required to meet recruitment criteria, a total of n = 34 (n = 17 per arm) were required to meet retention criteria, and a total of n = 38 (n = 19 per arm) were required to meet adherence criteria. Thus, our sample size was n = 40 (Alexander et al., 2025). This study was powered for feasibility outcomes. The CONSORT 2010 statement: extension to randomised pilot and feasibility trials guidelines recommend not conducting inferential statistics for effectiveness in pilot and feasibility studies. Therefore, we report descriptive statistics (mean and standard deviation or median and interquartile range (IQR) based on normality of the distribution of data) for lean mass, muscle strength, leg power, aBMD, functional balance, cardiorespiratory fitness, menopausal symptoms, and QoL. We also present 95% confidence intervals for each muscle and bone outcome for within-group and between-groups differences. As this was a feasibility trial, confidence intervals are provided for descriptive purposes only and should not be interpreted as hypothesis tests or evidence of efficacy. All analyses and figures were completed using R (R Core Team (2021). Version 4.4.0, Vienna, Austria). Analyses were conducted using outcome-specific complete cases; for each outcome, only participants with both pre- and post-intervention data were included. Results Participant characteristics Of the 40 participants enrolled in the trial, 38 completed follow-up testing (two participants in the WC dropped out; Fig. 1). Two additional participants dropped out of the intervention prior to the second strength phase due to undisclosed previous injuries; however, both completed follow-up assessments. A separate intervention participant sustained an injury outside the program, necessitating a modification of the exercise intervention, including not performing 1RM testing, but they continued to attend sessions and returned for follow-up assessments. We lost dominant and non-dominant handgrip and FSST data for one WC participant, and two intervention participants did not perform MVIC due to having high blood pressure. Consolidated standards of reporting trial flowchart. Baseline participant characteristics are shown in Table 1. At follow-up, the mean age (SD) was 53.7 (3.5) and 53.8 (4.6) years in the INT and WC, respectively. 47.5% of participants were peri-menopausal at baseline and 39.5% at follow-up. Three (two INT, one WC) participants (7.5%) were using MHT (combined estrogen and progesterone) at baseline. Two participants (one INT, one WC) stopped using MHT and four INT participants started MHT during the study (combined estrogen and progesterone, estrogen gel); thus, five participants (13.2%) were on MHT at follow-up. In terms of PA levels, 92.5% of participants met minimum wear time requirements at baseline, of which 94.6% met the CSEP PA guidelines of 150 min of MVPA per week (Dale et al., 2016). One participant met the ALMI sarcopenia criteria at baseline and follow-up, but their handgrip strength was above the 20 kg cutoff at both timepoints. Thus, they were not considered sarcopenic according to the European consensus and diagnostic criteria (Cruz-Jentoft et al., 2010). Fifteen participants were classified as having low bone mass (35% of INT and 44% of WC), and one INT participant as having osteoporosis. One participant with a high body mass was excluded from the estimated V̇O2max analysis due to being an outlier (implausibly low value at baseline and a negative value at follow-up), and another due to an ankle injury that impacted their performance at follow-up. Table 1Participant characteristics at baseline, mean (SD).Waitlisted controlled (n = 18)Intervention (n = 20)Overall (n = 38)Age (years)53.0 (4.7)52.9 (3.6)52.9 (4.1)Height (cm)165.4 (6.5)165.1 (5.1)165.2 (5.7)Body Mass (kg)72.3 (15.4)74.9 (20.5)73.6 (18.1)BMI (kg/m2)26.4 (5.5)27.5 (7.8)27.0 (6.8)Lumbar Spine (L1-L4) T-score0.36 (1.25)−0.02 (1.32)0.16 (1.29)Femoral Neck T-score−0.46 (0.99)−0.62 (0.73)−0.55 (0.86)Total Hip T-score0.12 (1.19)−0.15 (0.96)−0.02 (1.07)n peri-menopausal91019n MHT use123Time in sedentary per day (minutes)a747.5 (64.3)674.4 (83.7)708.9 (83.6)Time in MVPA per day (minutes)a42.3 (16.2)52.1 (22.4)47.5 (20.3)n: sample size; BMI: body mass index; MHT: menopausal hormone therapy; MVPA: moderate-to-vigorous physical activity.aFor accelerometer outcomes, n = 17 for waitlisted controlled, n = 19 for intervention and n = 36 overall due to missing data. Participant characteristics at baseline, mean (SD). n: sample size; BMI: body mass index; MHT: menopausal hormone therapy; MVPA: moderate-to-vigorous physical activity. For accelerometer outcomes, n = 17 for waitlisted controlled, n = 19 for intervention and n = 36 overall due to missing data. Change in muscle strength, lean mass, leg power, and aBMD Between week 12 and week 36 of the intervention, the INT experienced mean increases for 1RM of the deadlift (21.7 ± 12.9%), chest press (12.6 ± 14.6%), back squat (30.5 ± 19.7%), and shoulder press (15.3 ± 10.1%) (Fig. 2; Table 2). Increases in load lifted relative to body mass at the end of the intervention were 19.1 ± 9.3%, 5.4 ± 5.3%, 20.7 ± 9.5%, and 5.1 ± 3.3% for deadlift, chest press, back squat, and shoulder press, respectively (Fig. A.2). 1RM percent change over time for A) deadlift, B) back squat, C) chest press, and D) shoulder press (n = 17). Blue lines indicate individual participants, black line shows mean percent change. Four participants reported injuries unrelated to the intervention that temporarily reduced performance, resulting in individual values falling below baseline in specific phases. 1RM: one-repetition maximum. Table 2Intervention group (n = 17) median (IQR) 1RM values at week 12 (first 1RM test) and 36 (last 1RM test).Week 12 1RMWeek 36 1RMDeadlift (kg)65.8 (61.2 to 2.6)83.9 (72.6 to 91.9)Chest Press (kg)36.3 (29.5 to 43.1)37.7 (32.9 to 44.0)Back Squat (kg)55.79 (43.1 to 65.8)69.4 (59.0 to 78.2)Shoulder Press (kg)26.04 (22.7 to 29.5)29.71 (26.2 to 32.7)1RM: One-repetition maximum; data not normally distributed. Intervention group (n = 17) median (IQR) 1RM values at week 12 (first 1RM test) and 36 (last 1RM test). 1RM: One-repetition maximum; data not normally distributed. Baseline and follow-up measures of muscle and bone for the INT and WC are shown in Table 3. The INT experienced a mean increase of 1.2 ± 3.0% in total body lean mass, while the WC experienced a mean decline of 0.8 ± 2.8% (Fig. 3A). Appendicular lean mass increased by 2.2 ± 3.0% in the INT and declined by 0.9 ± 3.3% in the WC (Fig. 3B). The INT experienced mean increases of 2.7 ± 3.6% in arm lean mass and 2.1 ± 3.3% in leg lean mass, while the WC experienced mean decreases of 2.3 ± 4.2% and 0.5 ± 3.4% in arm and leg lean mass, respectively. For body mass and fat mass, the INT had mean increases of 0.8 ± 4.9% and decreases of 0.4 ± 12.8%, respectively, while the WC experienced mean decreases of 1.1 ± 4.5% and 1.9 ± 10.1% for body mass and fat mass, respectively. Table 3Outcome measures for the waitlisted controlled and intervention group at baseline and follow-up.Waitlisted controlledInterventionDifference within groupsDifference between groupsBaseline (n = 18)Follow-up (n = 18)Baseline (n = 20)Follow-up (n = 20)Waitlisted controlled (n = 18)Intervention (n = 20)Intervention – Waitlisted controlledMean (SD)Mean (SD)Mean (SD)Mean (SD)∆ Mean (SD) [95% CI]∆ Mean (SD) [95% CI]∆ Mean (SD pooled) [95% CI]Lean mass (kg)42.17 (4.84)41.80 (4.49)42.12 (7.15)42.64 (7.42)−0.38 (1.23) [−0.99, 0.23]0.52 (1.26) [−0.07, 1.11]0.90 (1.24) [0.08, 1.72]ALM (kg)18.85 (2.88)18.66 (2.75)18.85 (4.32)19.24 (4.32)−0.20 (0.64) [−0.52, 012]0.39 (0.53) [0.14, 0.64]0.59 (0.58) [0.20, 0.98]ALMI (kg/ht2)6.88 (0.91)6.81 (0.88)6.92 (1.60)7.05 (1.59)−0.07 (0.21) [−0.17, 0.04]0.14 (0.18) [0.05, 0.22]0.20 (0.19) [0.08, 0.33]Lumbar Spine aBMD (g/cm2)1.223 (0.150)1.216 (0.146)1.177 (0.157)1.190 (0.161)−0.006 (0.029) [−0.021, 0.008]0.013 (0.029) [0.000, 0.027]0.020 (0.029) [0.001, 0.039]Femoral Neck aBMD (g/cm2)0.974 (0.139)0.971 (0.139)0.951 (0.101)0.951 (0.101)−0.003 (0.018) [−0.011, 0.006]0.000 (0.024) [−0.012, 0.011]0.002 (0.022) [−0.012, 0.016]Total hip aBMD (g/cm2)1.024 (0.149)1.019 (0.146)0.988 (0.120)0.985 (0.117)−0.006 (0.014) [−0.013, 0.002]−0.004 (0.016) [−0.011, 0.004]0.002 (0.015) [−0.008, 0.012]Leg power (W)2048 (322)2020 (301)2002 (419)2071 (416)−28 (166) [−110, 55]70 (115) [16, 124]97 (141) [2, 193]Relative leg power (W/kg)28.52 (3.62)28.57 (3.80)27.36 (5.77)28.15 (5.85)0.05 (2.41) [−1.15, 1.25]0.79 (1.75) [−0.03, 1.61]0.74 (2.09) [−0.66, 2.15]MVIC (N•m)a122.42 (34.28)123.53 (30.07)118.26 (25.17)124.27 (24.36)1.12 (23.79) [−10.71, 12.95]6.01 (18.00) [−2.94, 14.96]4.89 (21.09) [−9.43, 19.22]Dominant handgrip strength (kg)b26.1 (6.65)26.9 (7.08)25.7 (5.12)27.3 (4.27)0.8 (3.2) [−0.8, 2.5]1.6 (3.5) [−0.1, 3.3]0.8 (3.4) [−1.5, 3.0]Non-dominant handgrip strength (kg)b24.2 (6.55)25.1 (5.96)24.1 (5.05)25.9 (5.13)0.8 (2.65) [−0.5, 2.2]1.8 (4.54) [−0.3, 3.9]1.0 (3.8) [−1.5, 3.4]FSST (s)b6.48 (1.10)6.24 (1.09)6.57 (1.12)6.42 (1.10)−0.24 (0.65) [−0.58, 0.09]−0.15 (0.77) [−0.51, 0.21]0.09 (0.72) [−0.38, 0.57]Predicted V̇O2max (mL/kg/min)c30.42 (5.48)31.00 (6.38)30.32 (5.31)30.72 (5.14)0.57 (2.15) [−0.50, 1.64]0.40 (1.67) [−0.43, 1.24]−0.17 (1.93) [−1.47, 1.14]ALM: appendicular lean mass; ALMI: appendicular lean mass index; MVIC: maximal voluntary isometric contraction; FSST: four-square-step test; aBMD: areal bone mineral density; CI: confidence interval.an = 18 for intervention group due to two participants not completing MVIC at baseline and/or follow-up due to high blood pressure.bn = 17 for waitlist controlled group due to a technical saving error.cn = 18 for intervention group due to one participant with a high body mass being excluded (implausibly low value at baseline and a negative value at follow-up), and another due to an ankle injury that impacted their performance at follow-up. Outcome measures for the waitlisted controlled and intervention group at baseline and follow-up. ALM: appendicular lean mass; ALMI: appendicular lean mass index; MVIC: maximal voluntary isometric contraction; FSST: four-square-step test; aBMD: areal bone mineral density; CI: confidence interval. n = 18 for intervention group due to two participants not completing MVIC at baseline and/or follow-up due to high blood pressure. n = 17 for waitlist controlled group due to a technical saving error. n = 18 for intervention group due to one participant with a high body mass being excluded (implausibly low value at baseline and a negative value at follow-up), and another due to an ankle injury that impacted their performance at follow-up. Boxplots of percent change for A) total lean mass, B) appendicular lean mass, C) absolute leg power output, and D) lumbar spine areal bone mineral density (aBMD). Dashed lines represent 0 % change, while red data points represent peri-menopausal participants and black data points represent early post-menopausal participants at baseline. Whiskers extend to 1.5 times the interquartile range. Absolute leg power output increased in the INT by 3.7 ± 5.6%, while the WC showed a mean decline of 0.9 ± 8.1% (Fig. 3C). Leg power output relative to body mass increased for both the INT (3.1 ± 6.4%) and the WC (0.5 ± 8.1%) (Fig. A.3A). MVIC increased in both the INT and WC (6.6 ± 15.9% and 4.1 ± 24.2%, respectively) (Fig. A.3B). Dominant and non-dominant handgrip strength increased by 8.3 ± 18.3% and 9.4 ± 22.3%, respectively, in the INT, and 3.6 ± 12.4% and 4.6 ± 10.4%, respectively, in the WC (Fig. A.3C and A.3D). The INT experienced a mean increase in lumbar spine aBMD of 1.1 ± 2.5% while the WC experienced a mean decrease of 0.5 ± 2.4% (Fig. 3D). Femoral neck aBMD was maintained in the INT (0.0 ± 2.6%) and declined in the WC (0.3 ± 1.9%) (Fig. A.4C), while the INT and WC experienced mean decreases of 0.3% ± 1.6% and 0.5% ± 1.6% for total hip aBMD, respectively (Fig. A.4D). Change in balance, cardiorespiratory fitness, menopausal symptoms, and QoL Time to complete FSST decreased in the INT and the WC by 1.5 ± 12.9% and 3.3 ± 9.4%, respectively (Table 3, Fig. A.4B). Estimated V̇O2max from the 6MWT increased in the INT by 1.7 ± 6.7% and in the WC by 1.5 ± 7.2% (Table 2, Fig. A.4A). Menopausal symptoms Due to the non-normally distributed results for menopausal symptoms and QoL, we present percent change using median and IQR (Table 4). For context, a decrease in value indicates fewer symptoms, which is a positive outcome. In the vasomotor symptom domain, the INT and WC experienced no change in median percent change, 0.0% (−28.6 to 0.0%) and 0.0% (0.0 to 7.5%), respectively. For the physical domain, median percent change decreased by 20.9% (−32.8 to 10.1%) in the INT compared to a median decrease of 1.3% (−25.9 to 24.4%) in the WC (Fig. A.5A). Likewise, median percent change for the psychosocial domain decreased by 12.4% (−27.5 to 18.4%) in the INT and increased by 10.1% (−13.6 to 55.3%) in the WC (Fig. A.5B). For the sexual domain, the INT experienced a median change of 0.0% (−50.7 to 0.0%) compared to a median decrease of 11.8% (−47.5 to 0.0%) for the WC. Table 4Baseline and follow-up scores for menopause symptoms and quality of life (median, IQR).Waitlisted controlledInterventionWaitlisted controlledInterventionBaseline (n = 18)Follow-up (n = 18)Baseline (n = 20)Follow-up (n = 20)∆ Follow-up − Baseline∆ Follow-up − BaselineMENQoLVasomotor1.0 (1.0, 2.4)1.0 (1,0, 2.5)2.5 (1.0, 4.0)2.5 (1.0, 3.1)0.0 (0.0, 0.4)0.0 (−1.0, 0.0)Physical2.3 (1.7, 2.8)2.2 (1.7, 3.2)3.2 (2.2, 3.9)2.4 (2.0, 3.2)−0.1 (−0.6, 0.6)−0.8 (−1.0, 0.3)Psychosocial2.3 (1.6, 3.2)2.9 (1.6, 4.1)3.0 (2.3, 3.7)3.0 (1.9, 3.6)0.3 (−0.2, 1.3)−0.3 (−0.9, 0.6)Sexual2.5 (1.0, 4.3)1.0 (1.0, 2.6)2.0 (1.0, 4.0)1.0 (1.0, 2.3)−0.3 (−1.3, 0.0)0.0 (−1.5, 0.0) QoLGeneral health67.5 (56.3, 75.0)60.0 (55.0, 68.8)57.5 (48.8, 75.0)62.5 (55.0, 86.3)−7.5 (−15.0, 5.0)10.0 (0.0, 21.3)Health change50.0 (50.0, 50.0)50.0 (50.0, 50.0)50.0 (50.0, 75.0)75.0 (50.0, 81.3)0.0 (0.0, 1.4)12.5 (0.0, 25.0)Physical functioning95.0 (90.0, 98.8)95.0 (90.0, 100)90.0 (85.0, 95.0)97.5 (85.0, 100.0)0.0 (−3.8, 5.0)5.0 (0.0, 10.0)Role physical87.5 (76.6, 98.4)100.0 (82.8, 100.0)87.5 (62.6, 100.0)90.6 (71.9, 100.0)0.0 (−4.7, 17.2)3.1 (−6.3, 18.8)Role emotional91.7 (75.0, 100.0)83.3 (66.7, 91.7)70.8 (58.3, 91.7)83.3 (64.6, 100.0)−4.2 (−16.7, 8.3)8.3 (−2.1, 16.7)Energy/fatigue53.1 (40.6, 62.5)56.3 (45.3, 68.8)50.0 (18.8, 57.8)50.0 (25.0, 56.3)3.1 (−10.9, 12.5)0.0 (−6.3, 6.3)Mental health80.0 (71.3, 85.0)72.0 (65.0, 83.8)72.5 (58.8, 76.3)75.0 (50.0, 81.3)−5.0 (−8.8, 5.0)−5.0 (−5.0, 10.0)Social functioning100.0 (75.0, 100.0)87.5 (75.0, 100.0)75.0 (59.4, 100.0)81.3 (62.5, 100.0)0.0 (−9.4, 9.4)0.0 (−3.1, 12.0)Pain87.5 (65.6, 87.5)75.0 (62.5, 87.5)75.0 (59.4, 87.5)62.5 (59.4, 78.1)0.0 (−12.5, 9.4)0.0 (−12.5, 3.1)MENQoL: Menopause specific Quality of Life questionnaire; IQR: Interquartile range; QoL. Baseline and follow-up scores for menopause symptoms and quality of life (median, IQR). MENQoL: Menopause specific Quality of Life questionnaire; IQR: Interquartile range; QoL. QoL Increases in values indicate an improvement in QoL. General health domain increased by a median of 18.5% (0.0 to 33.8%) in the INT, compared to a median decrease of 10.0% (−24.3 to 8.9%) in the WC (Table 4, Fig. A.5C). Median health change domain scores improved by 16.7% (0.0 to 62.5%) in the INT, compared to 0.0% (0.0 to 0.0%) in the WC (Table 4, Fig. A.5D). Median percent change improvements in the INT for other domains included physical functioning (5.3% (0.0 to 11.1%)), role physical (3.3% (−9.3 to 24.1%)), and role emotional (9.1% (−2.1 to 27.1%)) (Table 4). Comparatively, the WC experienced a median percent change of 0.0% (−3.8 to 5.3%) in physical functioning, 0.0% (−4.7 to 20.9%) in role physical, and − 4.5% (−22.9 to 12.2%) in role emotional (Table 4). The energy/fatigue, social functioning, and pain domains showed no median percent change from baseline in the INT (0.0% (−10.3 to 17.7%), 0.0% (−3.1 to 18.8%), and 0.0% (−21.3 to 4.2%), respectively), while the WC experienced an improvement in energy/fatigue (3.9% (−26.1 to 21.7%)), and no median percent change in social functioning and pain (0.0% (−9.4 to 10.7%), 0.0% (−13.8 to 10.7%)) (Table 4). Mental health domain decreased for both the INT (−5.6% (−6.8 to 14.3%)) and the WC (−5.7% (−10.3 to 5.9%)) (Table 4). Discussion This randomised waitlisted controlled feasibility trial is the first intervention in peri- and early post-menopausal female individuals to investigate the effects of a 9-month heavy strength and impact training intervention on lean mass, functional performance, bone health, menopausal symptoms, and QoL. Our findings show that participants in the intervention group increased total body lean mass, absolute leg power output, and lumbar spine aBMD relative to the waitlisted controlled group. In contrast, the waitlisted controlled group exhibited expected declines in lean mass, absolute leg power output, and lumbar spine aBMD. Our results highlight a potential broad and meaningful impact of heavy strength and impact training during the menopause transition. Both groups showed small improvements in MVIC and handgrip strength for their dominant and non-dominant hands. Although we were not powered to assess differences between menopausal status, visually the spread of the data between peri- and early post-menopause appeared consistent across all muscle and bone outcomes (see Fig. 3, Fig. A.3, Fig. A.4). Body composition and bone Cross-sectional age-related declines in lean mass are commonly reported at 0.81 kg per decade from 27 to 80 years old (Silva et al., 2010), with longitudinal declines of 0.06 kg per year from two years prior to the final menstruation to one year post the final menstruation (Greendale et al., 2019). The 0.52 kg improvements we observed over nine months demonstrate that such declines are modifiable, with gains equivalent to offsetting nearly a decade of typical age-related loss. The improvements in lean mass we observed are comparable to those reported in moderate and heavy strength training interventions in early (Maddalozzo et al., 2007) and late post-menopausal female participants (Watson et al., 2015). Typical trajectories during the menopause transition include losses of up to 10% of bone mass during menopause and the decade following (Recker et al., 2000), increasing the risk of fragility fractures and osteoporosis for female individuals. The Study of Women's health Across the Nation (SWAN) reported an annual loss of 2.46% in lumbar spine aBMD between one year before the final menstrual period and two years after the final menstrual period (Greendale et al., 2012). In comparison, our intervention group not only avoided the expected loss in lumbar spine aBMD, but increased lumbar spine aBMD after heavy strength and impact training. The gains we observed align with previous work in early post-menopausal female participants performing moderate-intensity strength training (Maddalozzo et al., 2007). Considering only six months of the intervention involved heavy strength and impact training, the observed gains highlight the capacity of targeted loading to produce meaningful skeletal benefits in a relatively brief timeframe. Physical function Cross-sectional research highlights overall declines in strength with aging (Lichtenstein et al., 2023; Metter et al., 1997). In our study, strength gains were evident from the 1RM assessments. By the end of the intervention, participants were deadlifting, on average, more than their body mass and back squatting approximately their body mass. These gains in strength align with those reported in previous work investigating a one-year moderate-intensity strength training intervention in early post-menopausal participants (Maddalozzo et al., 2007). Maintaining and improving muscle strength becomes increasingly important with age. As muscles attach to bone, stronger muscles generate greater internal forces on bone, stimulating adaptations that contribute to improved bone strength (Troy et al., 2018). Muscle power also plays a key role in healthy aging (Foldvari et al., 2000), and its decline occurs more rapidly than strength, especially after age 50 in female individuals (Metter et al., 1997). Estimated declines in muscle power are reported at 7.8% per decade in 40–64 year old female individuals (Lichtenstein et al., 2023), while our intervention improved leg power by 3.7%. This magnitude of gain is roughly equivalent to offsetting several years of expected age-related decline. Because muscle power strongly influences mobility and functional independence, maintaining or improving power during the menopause transition may play an important role in preserving overall muscle health and quality of life. Menopausal symptoms and QoL Vasomotor symptoms are the most commonly reported menopausal symptoms across peri- and post-menopausal populations (Harlow et al., 2012). We only explored descriptive statistics and did not evaluate between-group differences for vasomotor symptoms and QoL. Vasomotor symptoms did not change after our intervention; however, intervention participants reported substantial improvements in other menopausal symptoms across both psychosocial and physical domains. Psychosocial symptoms such as life dissatisfaction, memory issues, and impatience showed positive change, as did physical symptoms like muscle and joint pain, sleep issues, and fatigue. In contrast, the waitlisted controlled group did not report similar improvements in menopause symptoms. The most pronounced QoL changes emerged in the general health and health change domains, where intervention participants reported improvements after the 9-month intervention. In contrast, the waitlisted controlled group reported declines or no change in the general health and health change domains. These changes are consistent with earlier research demonstrating enhanced general health domain following strength training in post-menopausal women with vasomotor symptoms (Berin et al., 2022). Our findings suggest the capacity of heavy strength and impact training to support QoL during the peri- and early post-menopausal years. Strengths and limitations Strengths of the study include the recruitment of both peri- and early post-menopausal female participants in our heavy strength and impact training intervention. Our intervention was modelled on the LIFTMOR trial protocol (Watson et al., 2018) and exceeded the 10–12 weeks typically required to detect lean mass changes (Stark et al., 2012) as well as the approximate 6-month time frame of the bone remodelling cycle (Eleftheriou et al., 2012). Our program also surpassed American College of Sport Medicine's (ACSM) moderate-intensity strength training recommendations by implementing heavy loading (Yang, 2019). Additionally, the supervised nature of the intervention ensured exercises were performed safely and with proper technique. Limitations of the study include the small sample size that was powered for feasibility outcomes as opposed to the secondary outcomes; thus, adequately powered future trials are needed to confirm efficacy. As over half of our participants had normal aBMD at baseline, it is possible that the changes in aBMD we observed were lower than had we exclusively recruited individuals with low bone mass. Also, the MVIC assessments did not mirror the movement patterns of the exercises in the intervention, which may have limited our ability to detect intervention-related changes. The FSST may not be challenging enough for this demographic, as the test was validated to measure dynamic balance and fall risk in individuals over 65 years (Cleary and Skornyakov, 2017). Alternate assessments, such as the Y-balance test, which is a valid measure of dynamic balance in middle-aged females without a ceiling effect (Svensen et al., 2025), may be more appropriate. Finally, our cohort was highly active at baseline, which may reduce the generalizability, as participants may have been more motivated than the broader population. Conclusion Nine months of heavy strength and impact training improved total body lean mass, absolute leg power output, and lumbar spine aBMD in peri- and early post-menopausal female individuals. Future definitive trials conducted during peri- and early post-menopause are needed to confirm and build upon these timely findings. To date, few randomised controlled trials have examined the effects of strength training on muscle and bone outcomes in this demographic, and those that have predominantly used short (≤ 12 weeks), light-to-moderate intensity strength training programs (Whitman et al., 2025). Future work would benefit from adopting longer progressive programs, like the present heavy strength and impact training intervention, and from directly comparing outcomes between peri- and early post-menopausal participants to determine whether an optimal intervention window exists. If implemented on a broader scale, such programs may help alter the trajectory of muscle and bone loss, enhance quality of life, and ultimately reduce the risk of falls and fractures later in life. Abbreviations bone mineral density high-intensity resistance and impact training areal bone mineral density quality of life Strength Training for Osteoporosis Prevention during Early Menopause Consolidated Standards of Reporting Trials intervention group waitlisted controlled group menopausal hormone therapy Canadian Society for Exercise Physiology one-repetition maximum rate of perceived exertion four-square-step test dual X-ray absorptiometry appendicular lean mass index maximal voluntary isometric contraction countermovement jump six-minute walk test physical activity moderate-to-vigorous physical activity counts per minute menopause-specific quality of life questionnaire Medical outcomes study 36-item short form health survey interquartile range standard deviation Study of Women's health Across the Nation Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation American College of Sport Medicine CRediT authorship contribution statement Patrick W. Whitman: Writing – review & editing, Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation. Christina J. Alexander: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation. Leah Kaluta: Writing – review & editing, Writing – original draft, Methodology, Investigation. Meghan H. McDonough: Writing – review & editing, Methodology. Matthew J. Jordan: Writing – review & editing, Methodology. Emma O. Billington: Writing – review & editing, Methodology, Funding acquisition. Lauren A. Burt: Writing – review & editing, Methodology, Funding acquisition. Leigh Gabel: Writing – review & editing, Supervision, Resources, Project administration, Methodology, Funding acquisition. Funding University of Calgary seed grants (i.e., Clinical Research Fund, VPR Catalyst Grant, and a McCaig Institute for Bone and Joint Health Seed Grant), an Alberta Health Services Bone and Joint Strategic Clinical Network and McCaig Institute Translational Impact Grant, and a Canadian Institutes of Health Research (CIHR) Priority Announcement: Female Athlete Health (02571-000). The funders had no role in the analysis or interpretation of trial results. CJA received funding from the Canadian Institutes of Health Research (CIHR CGS—D; FRN-199267), PWW from CAN-TAP-TALENT: Canadian Training Platform for Trials Leveraging Existing Networks and the Canadian MSK Rehab Research Network - Trainee Conference Travel Support, and LK from the Canadian MSK Rehab Research Network - Trainee Conference Travel Support. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Leigh Gabel reports financial support was provided by Alberta Health Services. Leigh Gabel reports financial support was provided by Canadian Institutes of Health Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements We thank Sam Sutherland and Charley Hasselaar for their help with coordinating the study, as well as the trainers and many volunteers who helped during the training sessions. We also thank the participants for their participation in the study and continued support for women's health research. Footnotes A brief note on the use of sex and gender language throughout this study. Since menopause is a phenomenon experienced by people with ovaries, this study uses the term “female” as it refers to biological sex, while previous literature has traditionally used “woman”, which refers to gender identity. When reporting the results of relevant literature, we use the language presented in the original studies. Further, following recent recommendations for the reporting of sex and gender in exercise science, we use “female” as an adjective rather than a noun (Hagstrom et al., 2025). Contributor Information Patrick W. Whitman, Email: patrick.whitman@ucalgary.ca. Christina J. Alexander, Email: christina.alexander@ucalgary.ca. Leah Kaluta, Email: leah.kaluta@ucalgary.ca. Meghan H. McDonough, Email: meghan.mcdonough@ucalgary.ca. Matthew J. Jordan, Email: mjordan@ucalgary.ca. Emma O. Billington, Email: e.billington@ucalgary.ca. Lauren A. Burt, Email: lburt@ucalgary.ca. Leigh Gabel, Email: leigh.gabel@ucalgary.ca. Phases of the Strength Training for Osteoporosis Prevention during Early Menopause intervention. Reps: repetitions; M: months; 1 RM: one-repetition maximum. 1RM weight lifted relative to body mass for A) deadlift, B) back squat, C) chest press, and D) shoulder press.100 indicates weight lifted is equal to 100% of participants body mass (n = 17). Blue lines indicate individual participants, black line shows mean weight lifted relative to body mass. Four participants reported injuries unrelated to the intervention(Maddalozzo et al., 2007) that temporarily reduced performance, resulting in individual values falling below baseline in specific phases. 1RM: one-repetition maximum. Boxplots of percent change for A) relative leg power output, B) leg torque, C) dominant handgrip strength, and D) non-dominant handgrip strength. Dashed line represents 0 % change, while red data points represent peri-menopausal participants and black data points represent early post-menopausal participants. Whiskers extend to 1.5 times the interquartile range. Boxplots of percent change for A) predicted VO2max, B) four-square-step test, C) femoral neck aBMD, and D) total hip aBMD. Dashed line represents 0 % change, while red data points represent peri-menopausal participants and black data points represent early post-menopausal participants. Whiskers extend to 1.5 times the interquartile range. aBMD: areal bone mineral density. Boxplots of percent change for A) menopausal symptoms physical domain, B) menopausal symptoms psychosocial domain, C) QoL general health, D) QoL health change. Red points represent peri-menopausal participants and black points represent early post-menopausal participants. Whiskers extend to 1.5 times the interquartile range. For the purposes of visualization, the y-axis was truncated such that one value for plots B (150% change), C (540% change), and D (200% change) are not shown. QoL: quality of life. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.